Deciphera Pharmaceuticals (DCPH) Tops Q4 EPS by 5c

Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $48.3 million versus the consensus estimate of $45.81 million.

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c